Abstract:The targeting of 5-aminosalicylic acid (5-ASA), a first-line therapeutic agent for mild to moderate active ulcerative colitis (UC), to the site of inflammation has remained a challenge and an unmet requirement in the treatment of UC. However, nanoscale carriers for targeted drug delivery are promising for pharmacotherapy, and nanoparticles improve the pharmacokinetics of the loaded therapeutics based on their physical properties. To design and prepare 5‑ASA‑loaded silicon dioxide nanoparticles (5‑ASA‑SiO2 NPs), a micro‑emulsion method was conducted, and their respective therapeutic effects were validated in a mouse model of UC. Cytotoxicity of 5‑ASA‑SiO2 NPs was detected in vitro using the Cell Counting Kit‑8 method. The therapeutic effect of 5‑ASA‑SiO2 NPs was assessed based on their disease activity index (DAI), colon histopathology, myeloperoxidase (MPO) and levels of tumor necrosis factor‑α (TNF‑α) and interleukin‑6 (IL‑6). SiO2 NPs were successfully prepared, and cytotoxicity of 5‑ASA‑SiO2 NPs was identified as being similar to 5‑ASA and SiO2 NPs. DAI and colonic histopathology scores in the normal dosage, high dosage and the 5‑ASA‑SiO2 NP groups demonstrated a significant improvement when compared with the model group. DAI in the high dosage and 5‑ASA‑SiO2 NP groups also demonstrated a significant improvement when compared with the normal dosage group. However, MPO, serum IL‑6 and TNF‑α levels in normal dosage, high dosage and 5‑ASA‑SiO2 NPs groups were significantly lower than in the model group, and these indexes in the high dosage group and 5‑ASA‑SiO2 NP group were significantly lower than that in the normal dosage group. Expression of IL‑6 and TNF‑α mRNA in colonic mucosa in the normal dosage, high dosage and 5‑ASA‑SiO2 NP group was significantly lower than that in the model group. Colonic mucosal IL‑6 and TNF‑α mRNA expression in the high dosage and 5‑ASA‑SiO2 NP groups was significantly lower than that in the normal dosage group (P<0.05). In conclusion, 5‑ASA‑SiO2 NPs are a selective drug release system that target the inflamed colon, characteristics of UC, and can greatly increase therapeutic efficacy in UC.

Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice.

Preparation Of 5-Aminosalicylic Acid-Loaded Ph-Sensitive P(Ce-Maa-Eg) Microgels For The Treatment Of Ulcerative Colitis

5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis

Synthesis and Evaluation of a Prodrug of 5-Aminosalicylic Acid for the Treatment of Ulcerative Colitis.

A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis

Alginate/methacrylic Acid/calcium Ion-Based Ph-Sensitive Drug Delivery Hydrogel for the Treatment of Ulcerative Colitis

Sustained release of 5-aminosalicylic acid from azoreductase-responsive polymeric prodrugs for prolonged colon-targeted colitis therapy

Improving Drug Utilization Platform with Injectable Mucoadhesive Hydrogel for Treating Ulcerative Colitis

Negatively Charged Thermosensitive Hydrogel Loaded with Pectin Microspheres to Recover the Mucosal Barrier for Ulcerative Colitis Therapy

In vitro and in vivo study of a colon-targeting pH-sensitive hydrocortisone sodium succinate hydrogel

In Vitro and in Vivo Study of Ph-Sensitive and Colon-Targeting P(LE-IA-MEG) Hydrogel Microspheres Used for Ulcerative Colitis Therapy

pH and redox dual response nano-suppository for the treatment of ulcerative colitis

Colon-targeted Drug Delivery Systems for 5-Aminosalicylic Acid

Eudragit S100 coated iron oxide-chitosan nanocomposites for colon targeting of 5-aminosalicylic acid ameliorate ulcerative colitis by improving intestinal barrier function and inhibiting NLRP3 inflammasome

Synthesis, Colon-Targeted Studies and Pharmacological Evaluation of an Anti-Ulcerative Colitis Drug 4-Aminosalicylic Acid-Β-o-glucoside.

5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice

Effect of Hydrogel Drug Delivery System for Treating Ulcerative Colitis: A Preclinical Meta-Analysis

Oral formulation of 5-aminosalicylic acid-Hemoglobin bio-adhesive nanoparticles enhance therapeutic efficiency in Ulcerative Colitis mice: A preclinical evaluation

Leveraging thiol-functionalized biomucoadhesive hybrid nanoliposome for local therapy of ulcerative colitis

Azo-linked 5-ASA-coumarin prodrug: Fluorescent tracking for colonic drug release in UC treatment

Simple and versatile in situ thermo-sensitive hydrogel for rectal administration of SZ-A to alleviate inflammation and repair mucosal barrier in ulcerative colitis